Home / Knowledge Center /
Publication

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression, microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and overall survival in CC. The objective of this study was to further validate ColDx using formalin-fixed, paraffin-embedded specimens collected as part of the Alliance phase III trial, C9581.

Our conclusion is that ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors, includingMMRdeficiency. ColDx could be incorporated with the traditional clinical markers of risk to refine patient prognosis.

View Resource
Almac Logo

Diagnostic Services

Almac Diagnostic Services is a stratified medicine business specializing in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases.

Our global laboratories offer tailored solutions from discovery to commercialization including:

  • Biomarker discovery
  • Custom assay development & validation
  • DNA and RNA panels
  • Flexible CDx (Companion Diagnostic) development & commercialization models
  • Expert regulatory support
  • Bioinformatics & software development

Our focus is on the discovery, development and commercialization of diagnostic and CDx tests.  We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies